Greenwood Gearhart Inc. Boosts Holdings in Pfizer (PFE)

Greenwood Gearhart Inc. grew its stake in shares of Pfizer (NYSE:PFE) by 12.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 192,672 shares of the biopharmaceutical company’s stock after acquiring an additional 21,256 shares during the quarter. Pfizer comprises approximately 2.2% of Greenwood Gearhart Inc.’s portfolio, making the stock its 19th biggest position. Greenwood Gearhart Inc.’s holdings in Pfizer were worth $6,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of PFE. Security Asset Management increased its holdings in Pfizer by 6.1% in the 4th quarter. Security Asset Management now owns 22,827 shares of the biopharmaceutical company’s stock worth $827,000 after buying an additional 1,317 shares in the last quarter. Waldron LP increased its holdings in Pfizer by 6.0% in the 4th quarter. Waldron LP now owns 23,785 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 1,341 shares in the last quarter. Community Financial Services Group LLC boosted its position in Pfizer by 0.6% in the fourth quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock worth $7,856,000 after purchasing an additional 1,375 shares during the last quarter. TCI Wealth Advisors Inc. boosted its position in Pfizer by 2.0% in the fourth quarter. TCI Wealth Advisors Inc. now owns 71,284 shares of the biopharmaceutical company’s stock worth $2,582,000 after purchasing an additional 1,375 shares during the last quarter. Finally, Banced Corp boosted its position in Pfizer by 5.4% in the fourth quarter. Banced Corp now owns 26,667 shares of the biopharmaceutical company’s stock worth $965,000 after purchasing an additional 1,376 shares during the last quarter. Hedge funds and other institutional investors own 71.65% of the company’s stock.

Several analysts recently issued reports on the company. Jefferies Group reissued a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Monday, May 14th. Credit Suisse Group reissued a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Friday. JPMorgan Chase set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, May 8th. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, DZ Bank reaffirmed a “sell” rating on shares of Pfizer in a research note on Thursday, May 3rd. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $40.08.

NYSE PFE opened at $35.64 on Friday. The company has a market cap of $212.58 billion, a PE ratio of 13.45, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The firm had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 EPS. equities analysts expect that Pfizer will post 2.95 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.82%. The ex-dividend date of this dividend is Thursday, May 10th. Pfizer’s dividend payout ratio is currently 51.32%.

In other news, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $36,790. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. In the last three months, insiders have sold 380,349 shares of company stock worth $13,829,340. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply